Indianapolis, Indiana-headquartered Eli Lilly launched Copellor (Ixekizumab) in India to treat adults that have moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. The drug will also be available for the treatment of adult patients with active psoriatic arthritis. Psoriasis is a chronic auto-immune disorder of the...